We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

353 hedge funds and large institutions have $5.72B invested in Ionis Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 112 increasing their positions, 119 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 43

4% more funds holding

Funds holding: 339 → 353 (+14)

6% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 119

11% less capital invested

Capital invested by funds: $6.45B → $5.72B (-$735M)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

35% less call options, than puts

Call options by funds: $78.8M | Put options by funds: $120M

Holders
353
Holders Change
+14
Holders Change %
+4.13%
% of All Funds
9.51%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
58
Increased
112
Reduced
119
Closed
43
Calls
$78.8M
Puts
$120M
Net Calls
-$41.7M
Net Calls Change
-$37.3M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$36.1M
2
CS
Credit Suisse
Switzerland
+$30.3M
3
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
+$29.1M
4
First Trust Advisors
First Trust Advisors
Illinois
+$25M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$24.7M

Top Sellers

1
BFA
BlackRock Fund Advisors
California
-$126M
2
BA
BlackRock Advisors
Delaware
-$50.1M
3
EAM
Eagle Asset Management
Florida
-$46.5M
4
State Street
State Street
Massachusetts
-$42.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$42.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
201
Ladenburg Thalmann Financial Services
Florida
$794K -$65.8K -1,035 -7%
AB
202
Amalgamated Bank
New York
$793K +$117K +1,844 +15%
SG Americas Securities
203
SG Americas Securities
New York
$792K +$594K +9,338 +211%
MJP
204
Michael J. Puzo
$774K -$50.9K -800 -6%
CC
205
Capital Counsel
New York
$748K – – –
Janus Henderson Group
206
Janus Henderson Group
United Kingdom
$734K – – –
AIG
207
American International Group
New York
$725K -$4.69M -73,804 -85%
HCM
208
Highbridge Capital Management
New York
$711K +$785K +12,350 New
VAM
209
Visium Asset Management
New York
$696K -$744K -11,700 -49%
KeyBank National Association
210
KeyBank National Association
Ohio
$690K -$197K -3,098 -21%
AAM
211
Advisors Asset Management
Colorado
$682K +$327K +5,149 +77%
LS
212
Livforsakringsbolaget Skandia
Sweden
$673K – – –
GC
213
Globeflex Capital
California
$668K -$1.15M -18,100 -61%
Asset Management One
214
Asset Management One
Japan
$655K – – –
SAM
215
Shell Asset Management
Netherlands
$646K +$21.2K +334 +3%
Principal Financial Group
216
Principal Financial Group
Iowa
$598K -$724K -11,393 -52%
AWCI
217
Alpine Woods Capital Investors
New York
$576K – – –
EGM
218
Engineers Gate Manager
New York
$564K +$246K +3,868 +65%
TRCT
219
Tower Research Capital (TRC)
New York
$533K +$481K +7,568 +446%
MAM
220
Majedie Asset Management
United Kingdom
$524K +$388K +6,096 +203%
Zurich Cantonal Bank
221
Zurich Cantonal Bank
Switzerland
$508K +$5.91K +93 +1%
SEI Investments
222
SEI Investments
Pennsylvania
$507K +$42.7K +672 +8%
MLICM
223
Metropolitan Life Insurance Company (MetLife)
New York
$503K -$5.16M -81,088 -90%
PRCM
224
Pine River Capital Management
Minnesota
$501K +$553K +8,700 New
DL
225
Delta Lloyd
Netherlands
$491K +$217K +3,411 +67%
7 8
9
10 11

IONS Hedge Fund Activity: Q2 2015 in Review

353 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2015, worth a combined $5.72B — down 11% from $6.45B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new IONS positions and 43 closed out — a net gain of 15 holders — while 112 added to existing stakes and 119 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36.1M. The largest seller was BlackRock Fund Advisors, cutting an estimated $126M.

  • 353 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2015, up from 339 in Q1 2015.
  • Funds reported $5.72B of Ionis Pharmaceuticals stock for Q2 2015, down 11% quarter-over-quarter.
  • 58 funds opened new Ionis Pharmaceuticals positions in Q2 2015 and 43 closed out, a net change of +15 holders.
  • The largest Ionis Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $36.1M added.
  • The largest Ionis Pharmaceuticals seller in Q2 2015 was BlackRock Fund Advisors, an estimated $126M sold.

Based on aggregated 13F filings for Q2 2015.